FY2025 EPS Estimates for Omnicell Boosted by Zacks Research

Omnicell, Inc. (NASDAQ:OMCL - Free Report) - Investment analysts at Zacks Research upped their FY2025 earnings per share estimates for shares of Omnicell in a research note issued to investors on Tuesday, July 15th. Zacks Research analyst R. Department now anticipates that the company will earn $0.31 per share for the year, up from their previous estimate of $0.28. The consensus estimate for Omnicell's current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell's Q4 2025 earnings at $0.17 EPS.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.16 by $0.10. Omnicell had a return on equity of 4.60% and a net margin of 1.87%. The firm had revenue of $269.67 million for the quarter, compared to analysts' expectations of $260.18 million. During the same quarter in the previous year, the company earned $0.03 earnings per share. The firm's quarterly revenue was up 9.5% compared to the same quarter last year.

Other equities analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of Omnicell from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 12th. Bank of America boosted their price target on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, May 23rd. Benchmark lowered their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Piper Sandler reaffirmed an "overweight" rating on shares of Omnicell in a research note on Friday, May 23rd. Finally, Wells Fargo & Company reaffirmed an "overweight" rating and issued a $37.00 price objective (up previously from $35.00) on shares of Omnicell in a research note on Friday, May 23rd. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $44.83.

Omnicell Price Performance

Shares of NASDAQ OMCL traded down $1.09 during trading on Thursday, hitting $26.88. The company had a trading volume of 621,402 shares, compared to its average volume of 563,445. The company has a market cap of $1.26 billion, a P/E ratio of 58.44, a PEG ratio of 7.84 and a beta of 0.76. Omnicell has a 52 week low of $22.66 and a 52 week high of $55.75. The business's 50-day moving average is $29.10 and its 200 day moving average is $34.11. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.23 and a current ratio of 1.38.

Institutional Investors Weigh In On Omnicell

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Johnson Financial Group Inc. bought a new stake in shares of Omnicell during the 4th quarter worth about $37,000. Headlands Technologies LLC bought a new stake in Omnicell during the 4th quarter worth approximately $53,000. Huntington National Bank boosted its stake in shares of Omnicell by 236.4% in the 4th quarter. Huntington National Bank now owns 1,359 shares of the company's stock valued at $61,000 after purchasing an additional 955 shares during the last quarter. GAMMA Investing LLC boosted its stake in Omnicell by 37.1% during the second quarter. GAMMA Investing LLC now owns 1,694 shares of the company's stock worth $50,000 after acquiring an additional 458 shares in the last quarter. Finally, Point72 Hong Kong Ltd bought a new position in shares of Omnicell in the fourth quarter valued at $101,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.